Regenerative biotechnology

Gencell® CTM ACE 2+

Pre-stimulated mesenchymal stem cells for pulmonary therapeutic support.

Injectable solution of mesenchymal stem cells with increased ACE-2 expression, aimed at modulating inflammation, protecting the endothelium, and supporting pulmonary recovery in SARS-CoV-2 infection.
View technical sheet

Composition

Mesenchymal stem cells.

Pharmaceutical form

Injectable solution.

Presentation

Monovette with 4 ml.

Therapeutic Properties

They promote tissue repair through immunomodulation, inhibition of apoptosis, stimulation of cellular proliferation, and release of soluble ACE-2, contributing to immune regulation, endothelial protection, and pulmonary recovery.
  • Reduction of pulmonary inflammation.
  • Modulation of the immune response.
  • Inhibition of cellular apoptosis.
  • Stimulation of tissue regeneration.
  • Transdifferentiation at the site of injury.
  • Release of soluble ACE-2.
  • Reduction of viral internalization.
  • Protection of the pulmonary endothelium.

Mechanism of action & Clinical data

They migrate to injured tissue, modulate inflammation, inhibit apoptosis, stimulate regeneration, and release soluble ACE-2 that reduces SARS-CoV-2 internalization.

Indications

Adjunct in active SARS-CoV-2 infection and acute respiratory distress syndrome secondary to COVID-19.

Administration

Intravenous route via slow infusion diluted in 0.9% saline solution, without bolus.

Contraindications

Hypersensitivity to ACE-2 inhibitors or formula components. Diagnosis of neoplasia.

Storage

Store refrigerated between 2 and 8 °C, protected from direct sunlight. Do not freeze.
PRODUCT FOR EXCLUSIVE USE BY HEALTHCARE PROFESSIONALS. APPLICATION UNDER MEDICAL PROTOCOLS.

I want to be contacted

    CTM ACE 2+